Sipuleucel-T in prostate cancer: Indication of added benefit

Friday, March 20, 2015 - 11:30 in Health & Medicine

Regarding Sipuleucel-T for use in prostate cancer, information submitted by the drug manufacturer provided better evidence on mortality. However, it is not possible to exactly estimate the extent of added benefit.

Read the whole article on Science Daily

More from Science Daily

Learn more about

Latest Science Newsletter

Get the latest and most popular science news articles of the week in your Inbox! It's free!

Check out our next project, Biology.Net